Corcept Therapeutics has the GF Score of 82, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Corcept Therapeutics
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Corcept Therapeutics GF Score Related Terms
HAM:HTD vs PCVX, IBRX, HALO: GF Score Comparison
For the Biotechnology subindustry, Corcept Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's GF Score falls into.
Corcept Therapeutics (HAM:HTD) has a GF Score of 82 as of Jun. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Corcept Therapeutics and its competitors. This is 11% below median its historical median of 92.00. Over the past decade, Corcept Therapeutics' GF Score has ranged from 88.00 to 96.00.
Is Corcept Therapeutics' GF Score too high?
Corcept Therapeutics' current GF Score of 82 is 11% below median its 10-year median of 92.00. Over the past 10 years, this metric has ranged from a low of 88.00 to a high of 96.00. Overall, Corcept Therapeutics has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' GF Score compare to PCVX and IBRX?
Corcept Therapeutics' GF Score of 82 can be compared against companies in the Biotechnology industry. Historically, Corcept Therapeutics' own GF Score has ranged from 88.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current GF Score is 82, which is 11% below median its own 10-year median of 92.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current GF Score of 82. The stock's GF Value™ is €51.66, compared to a current price of €73.14 — trading 41.6% above its estimated fair value. The current GF Score is 82, which is 11% below median its 10-year median of 92.00. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current GF Score is 82 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €73.14 is trading 41.6% above its estimated GF Value™ of €51.66.
Key valuation signals for HAM:HTD:
GF Score: 82 (11% below median its 10-year median of 92.00)
GF Value™: €51.66 vs. price of €73.14 (41.6% above fair value)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for HAM:HTD
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 